Related references
Note: Only part of the references are listed.Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
Veronika Vikova et al.
THERANOSTICS (2019)
MRI Is a DNA Damage Response Adaptor during Classical Non-homologous End Joining
Putzer J. Hung et al.
MOLECULAR CELL (2018)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
E. Viziteu et al.
LEUKEMIA (2017)
Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN
Nausica Arnoult et al.
NATURE (2017)
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma
Matteo Marchesini et al.
CANCER CELL (2017)
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
David A. Alagpulinsa et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Niels Weinhold et al.
BLOOD (2016)
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells
Arghya Ray et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Small RNAs Recruit Chromatin-Modifying Enzymes MMSET and Tip60 to Reconfigure Damaged DNA upon Double-Strand Break and Facilitate Repair
Qinhong Wang et al.
CANCER RESEARCH (2016)
PAXX Is an Accessory c-NHEJ Factor that Associates with Ku70 and Has Overlapping Functions with XLF
Satish K. Tadi et al.
CELL REPORTS (2016)
A comprehensive survey of the mutagenic impact of common cancer cytotoxics
Bernadett Szikriszt et al.
GENOME BIOLOGY (2016)
RECQ helicases are deregulated in hematological malignancies in association with a prognostic value
Elena Viziteu et al.
BIOMARKER RESEARCH (2016)
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study
PeterM. Voorhees et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage
Wenwen Wu et al.
CANCER RESEARCH (2015)
The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
Rishil J. Kathawala et al.
DRUG RESISTANCE UPDATES (2015)
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma
Ruben Niesvizky et al.
LEUKEMIA & LYMPHOMA (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
Exploiting replicative stress to treat cancer
Matthias Dobbelstein et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins
Marianne S. Poruchynsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma
Francesca Cottini et al.
CANCER DISCOVERY (2015)
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Shaji K. Kumar et al.
BLOOD (2015)
PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R
Ting Xiong et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability
Ana B. Herrero et al.
PLOS ONE (2015)
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Anouk Caraux et al.
Oncotarget (2015)
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Silvia Park et al.
ANNALS OF HEMATOLOGY (2014)
The future of autologous stem cell transplantation in myeloma
Frits van Rhee et al.
BLOOD (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other
Sylvanie Surget et al.
LEUKEMIA & LYMPHOMA (2014)
Transcriptionally active chromatin recruits homologous recombination at DNA double-strand breaks
Francois Aymard et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
Manuel Luis Orta et al.
NUCLEIC ACIDS RESEARCH (2014)
A histone H3K36 chromatin switch coordinates DNA double-strand break repair pathway choice
Chen-Chun Pai et al.
NATURE COMMUNICATIONS (2014)
The Role of DNA Damage and Repair in Decitabine-Mediated Apoptosis in Multiple Myeloma
Ken Maes et al.
ONCOTARGET (2014)
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
Alboukadel Kassambara et al.
ONCOTARGET (2014)
Concerted Activities of Distinct H4K20 Methyltransferases at DNA Double-Strand Breaks Regulate 53BP1 Nucleation and NHEJ-Directed Repair
Creighton T. Tuzon et al.
CELL REPORTS (2014)
SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability
Sophia X. Pfister et al.
CELL REPORTS (2014)
Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation
Relja Popovic et al.
PLOS GENETICS (2014)
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer
N. J. Curtin
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma
Caroline Bret et al.
CELL CYCLE (2013)
DNA repair pathways in human multiple myeloma Role in oncogenesis and potential targets for treatment
Claire Gourzones-Dmitriev et al.
CELL CYCLE (2013)
Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe
Mauro Cives et al.
CELLULAR SIGNALLING (2013)
The Histone Methyltransferase MMSET Regulates Class Switch Recombination
Huadong Pei et al.
JOURNAL OF IMMUNOLOGY (2013)
Histone H4 deacetylation facilitates 53BP1 DNA damage signaling and double-strand break repair
Kuei-Yang Hsiao et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2013)
Repair of Strand Breaks by Homologous Recombination
Maria Jasin et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
AZD5438, an Inhibitor of Cdk1, 2, and 9, Enhances the Radiosensitivity of Non-Small Cell Lung Carcinoma Cells
Pavithra Raghavan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells
Heather J. Landau et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Prime, Repair, Restore: The Active Role of Chromatin in the DNA Damage Response
Gaston Soria et al.
MOLECULAR CELL (2012)
Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair cross-complementing protein 1 (XRCC1)
Cristian Boboila et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
DNA repair dysregulation from cancer driver to therapeutic target
Nicola J. Curtin
NATURE REVIEWS CANCER (2012)
Synthetic lethality: exploiting the addiction of cancer to DNA repair
Montaser Shaheen et al.
BLOOD (2011)
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Joaquin Martinez-Lopez et al.
BLOOD (2011)
RECQL1 and WRN Proteins Are Potential Therapeutic Targets in Head and Neck Squamous Cell Carcinoma
Akihito Arai et al.
CANCER RESEARCH (2011)
Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity
Radek Jorda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs
S. E. Fordham et al.
LEUKEMIA (2011)
Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair
Deniz Simsek et al.
NATURE (2011)
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
Huadong Pei et al.
NATURE (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Neil Johnson et al.
NATURE MEDICINE (2011)
Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining
Sheema Fnu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Wolf-Hirschhorn syndrome candidate 1 is involved in the cellular response to DNA damage
Ildiko Hajdu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
DNA interstrand crosslink repair and cancer
Andrew J. Deans et al.
NATURE REVIEWS CANCER (2011)
Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
C. Dumontet et al.
BONE MARROW TRANSPLANTATION (2010)
Non-Homologous End-Joining Gene Profiling Reveals Distinct Expression Patterns Associated with Lymphoma and Multiple Myeloma
Philippa L. Roddam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Chaperoning Histones during DNA Replication and Repair
Monica Ransom et al.
CELL (2010)
DNA interstrand crosslink repair in mammalian cells: step by step
Parameswary A. Muniandy et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2010)
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
Marco Ladetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination
Anne Bothmer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Increased Plasma-Immune Cytokines throughout the High-Dose Melphalan-Induced Lymphodepletion in Patients with Multiple Myeloma: A Window for Adoptive Immunotherapy
Maud Condomines et al.
JOURNAL OF IMMUNOLOGY (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
The DNA Damage Response: Making It Safe to Play with Knives
Alberto Ciccia et al.
MOLECULAR CELL (2010)
NHEJ and its backup pathways in chromosomal translocations
Michael R. Lieber
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
A critical role for the NFkB pathway in multiple myeloma
Yulia N. Demchenko et al.
ONCOTARGET (2010)
Mechanisms of double-strand break repair in somatic mammalian cells
Andrea J. Hartlerode et al.
BIOCHEMICAL JOURNAL (2009)
Dysfunctional homologous recombination mediates genomic instability and progression in myeloma
Masood A. Shammas et al.
BLOOD (2009)
The Target of the NSD Family of Histone Lysine Methyltransferases Depends on the Nature of the Substrate
Yan Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Impairment of APE1 Function Enhances Cellular Sensitivity to Clinically Relevant Alkylators and Antimetabolites
Daniel R. McNeill et al.
MOLECULAR CANCER RESEARCH (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
K. Noborio-Hatano et al.
ONCOGENE (2009)
Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models
Kazunobu Futami et al.
CANCER SCIENCE (2008)
Genome instability: a mechanistic view of its causes and consequences
Andres Aguilera et al.
NATURE REVIEWS GENETICS (2008)
Single-strand break repair and genetic disease
Keith W. Caldecott
NATURE REVIEWS GENETICS (2008)
Transcription-coupled DNA repair: two decades of progress and surprises
Philip C. Hanawalt et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Induction of mitotic cell death in cancer cells by small interference RNA suppressing the expression of RecQL1 helicase
Kazunobu Futami et al.
CANCER SCIENCE (2008)
Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma
Patrick J. Hayden et al.
HUMAN MOLECULAR GENETICS (2007)
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2007)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells
Yasuhiro Murakawa et al.
CANCER RESEARCH (2007)
Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template
R. Scott Williams et al.
BIOCHEMISTRY AND CELL BIOLOGY (2007)
Proteasome function is required for DNA damage response and Fanconi anemia pathway activation
Celine Jacquemont et al.
CANCER RESEARCH (2007)
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Phase III study of PSC-833 (Valspodar) in combination with vincristine, doxorubicin, and dexamethasone (Valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) - A Trial of the Eastern Cooperative Oncology Group
WR Friedenberg et al.
CANCER (2006)
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma:: results of a pilot study including biological aspects
JF Rossi et al.
BONE MARROW TRANSPLANTATION (2005)
Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds
AB Witte et al.
FREE RADICAL BIOLOGY AND MEDICINE (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Ki-67 proliferation index - Correlation with prognostic parameters and outcome in multiple myeloma
MG Alexandrakis et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2004)
Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis
HH Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination
PL Roddam et al.
JOURNAL OF MEDICAL GENETICS (2002)
Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma
VJ Spanswick et al.
BLOOD (2002)
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914)
P Sonneveld et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
How nucleotide excision repair protects against cancer
EC Friedberg
NATURE REVIEWS CANCER (2001)
Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)
LA Hazlehurst et al.
ONCOGENE (2000)
Immunodeficiency associated with DNA repair defects
AR Gennery et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Share Paper
